משתמש:בנצי/ארגז חול ??: אינקרטין

אינקרטינים הינם קבוצה של הורמונים המופרשים מ-??? הגורמים לעלייה בקצב (?) הפרשת אינסולין מתאי בטא באיי לנגרהנס בלבלב לאחר אכילה, עוד בטרם עלתה בדם רמת הגלוקוז (blood glucose - ???). הם גם גורמים להאטת קצב קליטת חומרי מזון (???) בזרם הדם על-ידי הקטנת קצב פינוי המעיים (? + gastric - ?), ועשויים להשפיע על כמות המזון הנצרכת (השפעה על מנגנון התאבון). כפי שניתן לצפות, הורמונים אלה גם מעכבים שחרור של גלוקגון מתאי אלפא באיי לנגרהנס. שתי המולקולות המועמדות העיקריות העומדות באמות-המידה של אינקרטין הם פפטיד דמוי-גלוקגון-1 ופפטיד מעכב-??? (הידוע גם כפוליפפטיד ??? תלוי-גלוקוז או GIP - [[]]). הן GLP-1 והן GIP מושתקים (???) במהירות על-ידי האנזים דיפפטידיל פפטידאז-4 [[]] (הצעת תירגום כלשהי ?, DPP-4).

GLP-1 and DPP-4 inhibitors

Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. As expected, they also inhibit glucagon release from the alpha cells of the Islets of Langerhans. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as: glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

GLP-1 (7-36) amide is not very useful for treatment of type 2 diabetes mellitus, since it must be administered by continuous subcutaneous infusion. Several long-lasting analogs having insulinotropic activity have been developed, and two, exenatide (Byetta) and liraglutide (Victoza), have been approved for use in the U.S. The main disadvantage of these GLP-1 analogs is they must be administered by subcutaneous injection.

Another approach is to inhibit the enzyme that inactivates GLP-1 and GIP, DPP-4. Several DPP-4 inhibitors that can be taken orally as a tablet have been developed.

History

In 1902, Bayliss and Starling proposed that the intestinal mucosa contains a hormone, secretin, that stimulates the exocrine secretion of the pancreas.

However, oral administration of extracts of intestinal mucosa failed to help several patients with type 1 diabetes. In 1932, La Barre proposed the name incretin for a hormone extracted from the upper gut mucosa, which caused hypoglycemia, and proposed a possible therapy for diabetes. In 1939–1940, based on their studies, Leow et al. concluded the existence of incretins was "questionable". No further research in this area was performed for about thirty years.

Recent research

In 1970, GIP was isolated and sequenced from intestinal mucosa (JC Brown). Originally named gastric inhibitory peptide, GIP was renamed glucose-dependent insulinotropic peptide in 1973 after Brown and Dupre showed GIP stimulates insulin secretion. However, initial research could not establish its utility as a treatment for diabetes. The anglerfish proglucagon peptide was sequenced in 1982 by Lund and co-workers. The human proglucagon gene was cloned in 1983 by G. Bell, et al., and the human proglucagon sequence was subsequently deduced. However, the entire GLP-1 molecule had no effect on insulin levels. Only one specific sequence of GLP-1 was found to have an insulinotropic effect: GLP-1 (7-36) amide. It is rapidly inactivated to GLP-1 (9-36) by DPP-4 with a plasma half-life of only 1–2 minutes. GIP is also rapidly inactivated by DPP-4 to GIP (3-42).

See also

• exenatide - first FDA approved drug that uses the "incretin effect"
• liraglutide - second FDA approved drug that uses the "incretin effect"

References

• Drucker DJ, Nauck MA (2006). "The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes". Lancet. 368 (9548): 1696–705. doi:10.1016/S0140-6736(06)69705-5. PMID 17098089. {{cite journal}}: פרמטר לא ידוע |month= (עזרה)
• Amori RE, Lau J, Pittas AG (2007). "Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis". JAMA. 298 (2): 194–206. doi:10.1001/jama.298.2.194. PMID 17622601. {{cite journal}}: פרמטר לא ידוע |month= (עזרה)תחזוקה - ציטוט: multiple names: authors list (link)

External links

• Glucagon.com - site of Dr D.J. Drucker's laboratory that studies incretins